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VITAMIN D AND INCIDENCE OF DEMENTIA IN THE “KUOPIO ISCHAEMIC 
HEART DISEASE RISK FACTOR STUDY” 
Vitamin D has been suggested to play a role in the reduction of cognitive decline via 
neuroprotection, immunomodulation and reduction of oxidative stress. This study was 
conducted using data from the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD), 
which is an ongoing population based cohort study designed to investigate the risk factors of 
cardiovascular and other chronic diseases in the middle-aged and aging men and women in 
eastern Finland. The aim of this study was to investigate the association between vitamin D 
status, cognitive functions and later progression to dementia. 
A total of 2629 men from the baseline cohort and 920 postmenopausal women from the 11-
year follow-up participated in this study. Serum vitamin D was assayed as serum 25-
hydroxycholecalciferol (25(OH)D3) using high performance liquid chromatography (HPLC) 
of stored samples. Cognition was examined using cognitive tests such as mini mental state 
examinations (MMSE); trail making test version A and C, Heaton visual reproduction test 
(VRT), Buschke selective reminding test (BSR), verbal fluency test (VFT); and dementia and 
Alzheimer’s diseases (AD) diagnosis by record linkage to the national drug special 
reimbursement register, national hospital discharge register and the national cause of death 
register using Finnish personal identification number. The association between 25(OH)D3 and 
cognition was examined by analysis of variance, while the association between 25(OH)D3 
and dementia and AD was examined by logistic regression analysis. 
The mean (SD) ages of the study participants at entry were 53.0 years (5.1) for men and 63.2 
years (6.5) for women. The mean (SD) serum 25(OH)D3 was 43.4 nmol/l (18.9, range: 7.8-
136.1 nmol/l) for men, and 44.8 nmol/l (17.6, range: 8.54 to 112.77nmol/l) for  women. The 
total follow-up periods were 20 years (7.0) for men and 12.3 years (2.7) for women. A 
statistical significant difference was observed in VFT (P = 0.02) between the women in 
highest and lowest serum 25(OH)D3 quartiles. After multivariable adjustment, women in 
lowest serum 25(OH)D3 had a 2.7 fold (95% CI 1.31-5.72 P trend = 0.01) risk of developing 
dementia and 2.8 fold (95% CI 1.28-5.91 P trend = 0.01) risk of developing AD compared to 
women in the highest serum 25(OH)D3 quartile. No statistically significance association was 
observed among men in neither cognitive test performance nor risk of developing dementia 
(1.2 95% CI 0.83-1.86 P trend = 0.14) nor AD (1.4 95% CI 0.83-2.10 P trend = 0.12).  
These data show an association between low levels of circulating serum 25(OH)D3 
concentration and cognitive impairment in the verbal memory test, and risk of developing 
dementia and AD in the women but not in men. 
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ABBREVIATIONS 
 
AD Alzheimer's Disease 
AIDS Acquired Immunodeficiency Syndrome 
BSR Buschke Selective Reminding Test 
CI Confidence Interval 
CERAD Consortium To Establish a Registry For AD 
DSM Diagnostic Statistical Manual of Mental Disorders 
DLB Dementia with Lewy bodies 
FTD Fronto-temporal Dementia 
HIV Human Immunodeficiency Virus 
ICD-10 International Classification of Diseases 10th revision 
KIHD Kuopio Ischaemic Heart Disease Risk Factor Study 
MMSE Mini Mental State Examination 
MCI Mild Cognitive Impairment 
MRI Magnetic Resonance Imaging 
NINCDS-
ADRDA 
National Institutes of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Dementia and Related Disorders Association 
NNR Nordic Nutrition Recommendation 
PET Positron Emission Tomography 
PTH Parathyroid Hormone 
RXR Retinoid X Receptor 
SD Standard Deviation 
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TMT Trail Making Test 
T B Tuberculosis 
UVB Ultraviolet light B 
VD Vascular Dementia 
VFT Verbal Fluency Test 
VRT Visual Reproduction Test 
VDR Vitamin D Binding Receptor 
Vitamin D Vitamin D2 or D3 
Vitamin D2 Ergocalciferol 
Vitamin D3 Cholecalciferol 
VDREs Vitamin D –Responsive Elements 
VDR Vitamin D Receptor 
25(OH)D 25-Hydroxy vitamin D 
25(OH)D3 25-Hydroxycholecalciferol (Calcidiol) 
1,25(OH)2D3 1,25-Dihydroxycholecalciferol ( Calcitriol) 
1,24,25(OH)3D3 1,24,25-Trihydroxy vitamin D 
WHO World Health Organization 
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1 INTRODUCTION 
 
Vitamin D is a steroidal hormone that has been extensively described in the metabolism of 
calcium, phosphorous and in bone mineralization (Holick and DeLuca 1972, Holick 2007). 
Reduced exposure to sunlight and insufficient intake of foods with high vitamin D contents 
have resulted in deficiency of vitamin D in humans (Holick 2007).  
 
It is estimated that about 1 billion people in the world are vitamin D deficient or insufficient 
with higher prevalence in older people aged 65 years and over (Holick and Chen 2008). 
Sunlight exposure has been shown to be the major source of vitamin D for humans 
(Langunova et al. 2013). Food products are also good sources of vitamin D and these include 
salmon, sardines, tuna, cod liver, mushrooms, and most milk products are also fortified with 
vitamin D, for instance milk fortification became a health policy in Finland since 2003 
(Laaksi et al. 2006, Holick 2007).  
 
Finland is in the northern part of Europe with latitudes 60oN and 700N resulting in prolong 
cold periods and often darker day times and during the winter months, there is a low exposure 
to ultraviolet B (UVB) radiation, thus, reducing the synthesis of vitamin D (Lamberg-Allardt 
et al. 2001).  As a result, low vitamin D status has been mentioned among the Scandinavians 
(Lamberg-Allardt et al. 2001) including the Finns (Virtanen et al. 2011). 
 
Vitamin D deficiency has been defined as concentration of 25-hydroxycholecalciferol 
(25(OH)D3) lower than 50 nmol/l (20ng/dl) (Holick 2007) and it has been linked to many 
disease conditions such as dementia, Alzheimer's disease (AD) (Annweiler et al. 2010), 
cardiovascular diseases (Wang et al. 2008), depression (Lapid et al. 2013), pneumonia 
(Aregbesola et al. 2013), diabetes (Chakhtoura and Azar 2013) and cancer (Garland et al. 
2006). 
 
Cognition is the term used to describe mental processes such as memory, attention and 
executive functioning. The areas in the brain controlling these functions include the 
hippocampus, hypothalamus, the cortex and the sub cortex (Ridderinkhof et al. 2004). 
Cognitive dysfunction can occur temporarily as in delirium (de Lange et al. 2013), stable as 
in mild cognitive impairment (MCI) (Annweiler et al 2010) or progressively in dementia, 
which is a cascade of neurodegenerative processes resulting in irreversible decline in 
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cognitive functions clinically evident by loss of memory and autonomy (Sulkava et al.1985). 
Dementia is associated with high mortality in the elderly (Lönnroos et al. 2012). The 
etiopathology is a complex of inflammation, oxidative stress, neurotoxicity and genetics 
(Annweiler et al. 2010). The most common types of dementia include AD, vascular 
dementia, mixed dementia, dementia with Lewy bodies, and fronto-temporal dementia (Lobo 
et al. 2000, Langa et al. 2004, Qui et al. 2009, Querfurth and LaFela 2010).  
 
The role of vitamin D in brain functions has been described extensively in humans (Kalueff 
et al. 2004, McGrath et al. 2004, Eyles et al. 2005) and in animals (Burne et al. 2006). The 
active form of vitamin D (1,25(OH)2D3) has been found to have neuroprotective (Wang et al. 
2001, Kalueff et al. 2004), and vasculo-protective functions (Grant 2011). In Finland it has 
been shown that there is a high level of vitamin D deficiency especially in the geriatric 
population due to low levels of dietary vitamin D intake and reduced exposures to sunlight 
(Lamberg-Allardt et al. 2001) and that this deficiency associates with all cause morbidity and 
mortality (Virtanen et al. 2011). Prevalence of dementia across Europe is 6.4% per 100,000 
of people aged 65 and above; 4.4% for AD and 1.6% for vascular dementia (Lobo et al. 
2000). Incidence of dementias increases with age and latitude: it is higher among the elderly 
in Northwest Europe compared with Southern European countries (Fratiglioni et al. 2000). 
 
This study was designed to determine the association between vitamin D and cognition using 
the Kuopio Ischemic Heart Disease risk factor (KIHD) study. The KIHD study is a 
prospective population-based study aimed at investigating the risk factors of cardiovascular 
and common illnesses in Kuopio and surrounding communities (Virtanen et al. 2011).  
Cognitive impairment was assessed under two major categories such as dementia and AD. 
Although several epidemiological studies have accessed the association between vitamin D 
status and cognitive function (Annweiller et al. 2010, 2012, Peterson et al. 2012, Slinin et al. 
2012, Breitling et al. 2012, Afzal et al. 2013), only a few prospective population-based 
studies (Llewelly et al. 2010, Slinin et al 2010, Annweiller et al. 2012, Breitling et al. 2012) 
have examined the association between 25(OH) D and cognitive function, and none to the 
best of our knowledge among the aging Finns.  
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2 LITERATURE REVIEW 
 
2.1 Vitamin D 
Vitamin D is a steroidal hormone that is synthesized from 7-dehydrocholesterol in the skin 
cells, during exposure to sunlight. The ultraviolet B portion of the sunlight spectrum 
permeates the viable skin and is absorbed by 7-dehydrocholesterol, which is immediately 
converted to a pre-vitamin D3 and within the plasma to cholecalciferol (vitamin D3) (Holick 
and DeLuca 1972). It is a well know vitamin for its activities in metabolism of calcium, and 
phosphorus in bone mineralization. 
 
The chemical processes leading to the formation of vitamin D3 are highly energy dependent. 
The natural productions of vitamin D have been shown to be highly varied depending on the 
time of day, seasonal changes, latitudinal location, skin pigmentation and ageing (Holick and 
Chen 2008). Some food items contain vitamin D3. Major dietary sources include salmon, 
sardines, tuna, cod liver, and mushrooms while some dairy products fortified with vitamin D3 
include milk, cheese, yogurt and in some juices. However, these are not enough to meet daily 
requirement and thus there is need for including supplement intakes. The vitamin D2 
(ergocalciferol) occurs in plants, while vitamin D3 (cholecalciferol) in humans and animals 
(Holick and Chen 2008, Holick et al. 2008). Vitamin D2 is the most common form in 
supplementation and it has been found to be as effective in maintaining serum levels of 
25(OH)D3 as vitamin D3 (Holick et al. 2008). 
 
2.1.1 Epidemiology of vitamin D deficiency 
The prevalence of vitamin D insufficiency or deficiency is above 1 billion worldwide 
(Querfurth and LaFela 2010).  The insufficiency of vitamin D3 is defined as concentration of 
25(OH)D3 less than 75 nmol/l, while deficiency is described as concentration less than 50 
nmol/l (Holick 2007). Low concentrations have been described extensively in skeletal 
abnormalities, cardiovascular diseases, metabolic disease, pulmonary diseases, cancer, and 
all-cause mortality (Garland et al. 2006, Holick 2007, Wang et al. 2008, Virtanen et al. 2011, 
Aregbesola et al. 2013). Vitamin D3 insufficiency is common in institutionalized or house 
bound individuals such as the older people, or obese individuals, pregnant and lactating 
women, dark skinned people and dwellers at northern hemisphere during winter (Lamberg-
Allardt et al. 2001, Holick and Chen 2008). 
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Vitamin D3 deficiency has been described to play critical role in several chronic illnesses. A 
review of previous studies describes the possible roles of vitamin D in chronic disease such 
as in metabolic syndrome, cardiovascular diseases, and renal diseases, and in immunity 
(Makariou et al. 2011). While, Evidence from the literature showed that low serum vitamin 
D3 concentration is highly prevalent among the elderly and has been implicated in several 
chronic illness including cognitive decline and dementia (Scuteri et al. 2005, Annweiller et al 
2010, Makariou et al. 2011, Slinin et al. 2012, Breitling et al. 2012) and associated with 
higher all-cause mortality (Virtanen et al. 2011). 
 
2.1.2 Vitamin D metabolism 
Cutaneous production of vitamin D3 contributes over 90% of the serum concentration of the 
steroidal hormone vitamin D3 (Lehmann and Meurer 2010). The UVB absorption is 
influenced by melanin in the skin, and also by the angle to the sun; consequently, dark-
skinned persons require a longer sun exposure for the production of vitamin D3, which is 
accentuated during the winter period. The exposure to sunlight UVB causes photolysis of 7-
dehydrocholesterol, causing it to 9,10-seco-sterol pre-vitamin D3 (Precholecalciferol) in the 
viable skin. 
 
The pre-vitamin D3 is inactive and so requires a non-enzymatic activation to cholecalciferol 
in the skin. This conversion is temperature dependent and 50% of the pre-vitamin D3 can be 
converted within the first 12 to 24 hours of sun exposure (Lehmann and Meurer 2010). 
Thereafter, it is bonded to the vitamin D-binding protein (DBP), and transported to the liver 
where enzymatic hydroxylation to 25(OH)D3 occurs.  
 
The 25(OH)D3 is inactive, but is the main circulating form of vitamin D3, which is usually 
assayed in determining the levels of vitamin D in the human body. 25(OH)D3 bounds to the 
carrier protein DBP and is transported to the kidney where further hydroxylation occurs via 
the enzyme hydroxylase, to the biological active form 1,25-Dihydroxycholecalciferol  
(1,25(OH)2D3) and is further transported to the various body tissues especially the bone, 
intestine and the parathyroid gland where it is absorbed by the vitamin D receptor (VDR). In 
this form, it functions actively in the metabolism of calcium and phosphorus in bone 
mineralization. The hydroxylation processes by hydroxylase are tightly regulated by the 
parathyroid hormone.  
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2.1.3 Recommended intake of vitamin D3 
Vitamin D3 recommended intakes varies in different countries. The population reference 
intake recommended by the European Community Scientific Committee for Food (SCF) for 
daily vitamin D3 intake of 10–25 µg/day among 6–11 months, 10 µg/day among 1–3 years, 
7.5 µg/day among adults 18–64 years. The value recommended for pregnant or lactating 
women and adults older than 65 is 10 µg/day (Hautvast 2008). The upper limit of intake is 
placed at 50 µg/day based on the results of clinical trial for safety (Vieth et al. 2001).  
 
However, some European countries have different daily intake recommendation. Many 
countries recommend 10 µg/day of vitamin D3 especially for infants from 4 weeks, 7.5 
µg/day for children, 5 µg/day for adolescent till middle age; 10 µg /day for those older than 
65 years and for pregnant and lactating women 5 µg/day (Pedersen et al. 2008). The Nordic 
Nutritional Recommendation (NNR 2004) recommends 7.5 µg/day for persons older than 2 
years until middle age, but the recommendations are constantly been evaluated based on 
research findings. For example the Nordic recommendation for intake of vitamin D3 revised 
in October 2013 has the recommended dosage of vitamin D3 increased for children above 2 
years and adults from 7.5 µg/day to 10 µg/day: while for the elderly above 75 years is has 
been increased from 10 µg/day to 20 µg/day (NNR 2013). Table 1 compares the World 
Health Organization/Food and agricultural organization recommended nutrient intake, 
European commission population reference intake and Nordic nutrition recommendation as at  
2004 with the revised version in 2013.   
14 
 
Table 1: Daily dietary vitamin D intake (µg/day) by World Health Organization, European 
Union and in the Nordic nutrition recommendation 
Age, year WHO/FAO 
(RNI) 2005 
European commssion 
PRI 2003  
NNR 2004 NNR 2013 
< 1 5 7.5 10 10 
1-3  5 5 7.5 7.5 
4-10  5 5 7.5 10 
11–17  5 7.5 7.5 10 
18–50  5 5 7.5 10 
51–64  10 5 7.5 10 
65–74 15 10 10 10 
> 75 15 10 10 20 
Pregnant and 
lactating women 
5 10 7.5 7.5 
Source: European micronutrient recommendation (Doets et al. 2008) 
WHO/FAO World Health Organization/ Food and Agricultural Organization, Nordic 
countries: Denmark, Finland, Norway, and Sweden 
RNI: Recommended nutrient intakes, PRI: Population reference intake, NNR: Nordic 
nutrition recommendation 
 
Unit of vitamin D conversion  
Vitamin D intake: 1 IU = 25 ng, 40 IU = 1 µg, 200 IU = 5 µg, 400 IU = 10 µg, 
Serum vitamin D: 100 nmol/l = 40 ng/ml, 1 ng/ml = 2.5 nmol/l 
 
Physiologic value of vitamin D 
Vitamin D deficiency is defined as concentration of serum 25(OH)D3  less than 50 nmol/l (20 
ng/ml). Concentration of 51–74 nmol/l (21–29 ng/ml), are considered to indicate vitamin D 
insufficiency; concentrations 75 nmol/l (>30 ng/ml) is considered to be vitamin D sufficiency 
(Holick 2008) 
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2.1.4 Vitamin D extra-skeletal activities 
Most organs of the body as well as immune cells have vitamin D receptors and respond to 1, 
25(OH) D3. Also, some of these tissues and cells express the enzyme 1 α-hydroxylase 
(Holick 2007). Serum 1,25(OH)2D3 and its synthetic analogs are being recognized for their 
potent anti-proliferative, pro-differentiating, and immuno-modulatory activities which are 
mediated through the vitamin D receptor (VDR) in different tissues (Nagpal and 
Rathnachalam 2005). These VDRs belong to the steroid thyroid hormone nuclear receptor 
family. 
The active hormone 1,25(OH)2D3 binds to the nuclear receptor VDR which interacts with 
another nuclear receptor retinoic acid X receptor (RXR). Vitamin D catalyzes the complex 
VDR/RXR, which then bind to small sequence of DNA, referred to as the vitamin D response 
elements (VDREs), thereby initiating molecular reactions in genes in body tissues including 
the brain (Buell and Dawson-Hughes 2008). Evidence shows there are metabolic pathways 
for vitamin D in the brain with its extensive functions in cognition (Kalueff et al. 2006, Buell 
and Dawson-Hughes 2008). 
 
The active steroidal hormone vitamin D acts as a potent immunomodulator by its ability to 
inhibit the production of lymphokines and monocyte-derived cytokine leading to inhibition of 
helper T cells (Jirapongsananuruk et al. 2000). Vitamin D3 triggers direct antimicrobial 
response against intracellular bacterial (Liu et al. 2006) as revealed by the increased 
susceptibility for tuberculosis in subjects with low serum vitamin D3 (Chan 2000). 
 
2.1.4.1 Vitamin D in diabetes mellitus 
Subjects with low serum vitamin D are at increased risk of developing insulin resistance. 
Studies have shown the presence of extra-renal expression of 25 hydroxyvitamin D3-1 α-
hydroxylase in pancreatic islet cells (Bland et al. 2004). Vitamin D3 has also been found to 
improve the target cell sensitivity to insulin, and protecting pancreatic beta cells from 
immune attacks (Chiu et al. 2004). The level of vitamin D3 was similarly shown to be low at 
the onset of type 1 diabetes (Borkar et al. 2010, Chakhtoura and Azar 2013), and 
supplementation has been suggested for prediabetes patients to prevent progression to type 2 
diabetes. (Deleskog et al. 2012). 
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2.1.4.2 Vitamin D in cardiovascular diseases 
Evidence abounds in the role of vitamin D in cardiovascular health. Oral supplementation of 
the vitamin reduces systolic blood pressure in interventional studies (Pfeifer et al. 2001), and 
when vitamin D deficiency subjects were exposed to UVB radiation three times a week for 
three months, results showed an increase in the level of 1,25(OH)2D3 and reduction in both 
systolic and diastolic blood pressure (Krause et al. 1998). In addition, observational studies 
showed increase in incident cardiovascular events in participants with low vitamin D (less 
than 25 ng/ml) status when compared with those with values greater than 75 ng/ml (Wang et 
al. 2008). Pilz and collegues linked low levels of vitamin D with prevalent myocardial 
dysfunction and death from heart failure (Pilz et al. 2008) 
 
2.1.4.3 Vitamin D in other diseases 
Vitamin D supplementation has been recommended for improve mental health (Motsinger et 
al., 2012), cancer prevention (Garland et al. 2006). Vitamin D plays a potential role as a 
therapeutic agent in inflammatory diseases (rheumatoid arthritis, psoriatic arthritis), and in 
dermatological conditions such as psoriasis, actinic keratosis, seborrheic dermatitis (Lehmann 
and Meurer 2010, Tremezaygues and Reichrath 2011). 
 
2.1.5 Vitamin D in the nervous system 
Earlier studies described the presence of VDR in the brain of experimental animals using 
autoradiographs (Stumpf et al. 1982), and in the human cerebrospinal fluid (Balabanova et al. 
1984). The human brain was shown to be a target tissue when its regulatory effect on 
neuronal choline actyltranseferase and nerve cell growth factor were reported (Sonnenberg et 
al. 1986). Studies have suggested a major role of vitamin D in the central nervous system 
with the expression of the binding receptor VDR in several brain structure such as the in the 
hippocampus and cerebral cortex which are active areas in cognitive functions (Kaleuef et al 
2004).  
 
The hormone 1, 25(OH)2D3 was shown to be present in early gestation where it is involved in 
neurogenesis; also in later life of animals, in the sub ventricular zone where it functions in 
maintenance of neural stem cells (Veenstra et al.1998). It circulates in the blood as a 
complex, crossing the blood brain barrier and bounds to the VDR in the brain. The VDRs are 
found in the brain neurons, glia cells, macrophages in areas such as the temporal lobe, 
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cingulate cortices, thalamus, cerebellum, the hippocampus, hypothalamus, and the cerebral 
cortex, sub cortex and in the spinal cord (Kalueff et al. 2004, Annweiller et al. 2011). 
 
Functions of vitamin D in the nervous system include neuroprotection, immunomodulation, 
and reduction of oxidation. Neuroprotective functions are mediated via the multiple 
mechanisms of reduction of calcium neurotoxicity (Kalueff et al. 2004), regulation of 
gluthatione metabolism (Garcion et al. 1996), reduction of nitric oxide synthesis (Garcion et 
al. 1998), induction of neurothrophins (Kalueff et al. 2004), and protection of the neuronal 
cells against superoxides and peroxides (Ibi et al. 2001). The immune-modulatory properties 
of vitamin D are expressed via it actions as an immune suppressing activities. It acts by 
induction of anti-inflammatory cytokines (i.e. interleukin 4, transforming growth factor), 
while suppressing expression of proinflamatory cytokine (i.e. interleukin 6, tumor necrosis 
factor and macrophage colony stimulating factor) (Kalueff et al. 2004, 2006).  
 
The antioxidant properties are mediated through the process of detoxification and synthesis of 
neurotropic factors. Neurotropins like the neurotropin-3 and glial cell line derived neurotropic 
factor are proteins with receptor in several brain cells in areas such as the hippocampus and 
the neocortex, where they act as growth factors promoting survival and differentiation of 
developing neural cells; also maintaining and protecting the mature neural cells (Siegel and 
Chauhan, 2000). Other functions include the up regulation of glia hemeoxygenase-1 and 
down regulation of glia fibrillary acidic protein (Kalueff et al. 2004). 
 
In addition, the enzyme 1α-hydroxylase is found in the Purkinje cells and in the neuronal glia 
cells of the cerebral cortex. This enzyme catalyzes the activation of the hormone 25(OH)D3 to 
the active 1,25(OH)2D3 in the brain areas active in cognition (Eyles et al. 2005). 
 
2.2 Cognition 
Cognition is defined as the combination of skills, including attention, learning, memory, 
language and praxis, executive functions such as decision making, goal setting, planning and 
judgment (Fillit et al. 2002). Cognition can be influenced by the environment, level of 
education, and most importantly chronological age (Scuteri et al. 2005).  With normal ageing, 
individual differences occur in executive functioning i.e. the ability to processing new or 
learn new information or solving problems (Craik and Bialystok 2006).  
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2.2.1 Risk factors for cognition decline 
Several factors interplay during the life course in the process of developing cognitive 
impairment. Genetics as well as ageing has been described as strong non-modifiable risk 
factors in the development of dementia especially in AD. However, the modifiable risk 
factors include several vascular and environmental factors, which culminate into the process 
of neurodegeneration resulting into irreversible loss of cognitive performance. These can be 
described as vascular factors and psychosocial factors.  
 
Cognitive impairment is a public health issue with high prevalence among the elderly. There 
is evidence that mental function decline increases with age, independent of educational 
background, depression nor prevalent cerebrovascular accidents (Scuteri et al. 2005). The 
normal aging brain has been described to be associated with progressive structural changes in 
the brain neuronal network and clinically, cognitive impairment is categorized into age 
associated cognitive decline (AACD), mild cognitive impairment (MCI) and dementia 
(Grossberg and Desai 2006). The prevalence of age associated cognitive decline (AACD) 
increases with age and has been observed to be higher in the male gender (Hanninen et al. 
1996). Mild cognitive impairment (MCI) refers to impairment in cognitive functions that do 
not fall under the category of dementia; it is a heterogeneous condition where there are mild 
cognitive changes with various underlying aetiologies (Dubois et al. 2010). 
 
The vascular risk factors include presence of midlife high total cholesterol and high midlife 
systolic blood pressure elevated body mass index (over weight or obesity), type 2 diabetes 
mellitus, cerebrovascular diseases and stroke, excess alcohol consumption and smoking 
(Kivipelto et al. 2001, 2002, Qui et al 2010). Psychosocial risk factors include low levels of 
education, which is independent of levels of socio economic status (Farfel et al. 2013). Also, 
low levels of physical activities especially during the leisure time have been associated with 
cognitive decline (Rovio et al. 2005, Tolppanen et al. 2012). 
 
2.3 Dementia 
Dementia is not a disease entity but a term used in describing a chronic condition, insidious 
in onset, with progressive decline of intellectual capacity, which eventually leads to a gradual 
restriction of customary daily living activities unrelated to changes of alertness, mobility or 
consciousness (Grossberg and Desai 2006). However, some definition of dementia recognizes 
it as a neurodegenerative disorder with the presence of an initial memory decline. The 
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Diagnostic Statistical Manual for Mental Health fourth edition (DSM IV American 
psychiatric association, 1994) categorizes dementia as a neurocognitive disorder. Diagnostic 
criteria require a diagnosis of memory loss (Table 2), and impairment in one or more other 
cognitive domains, severe enough to affect social and daily functioning. There must be 
evidence of significant decline from the persons previous level of performance in more than 
one cognitive domain, this must be severe to interfere with the person ability to function 
normally in everyday activities, requiring help with complex activities; and the deficit cannot 
be explain by other mental disorders. Cognitive domain includes: Learning and memory, 
complex attention (to sustain, divide and select attention), executive function (to plan make a 
decision, work on memories, respond to feedback, inhibitions and mental flexibilities), 
language (expressive language, grammar and syntax and repetitive language), perceptual 
motor cognition (visual perception, visual construction, perceptual-motor, praxis and gnosis) 
and social cognition. 
 
Table 2: Definition dementia Diagnostic and Statistical Manual of Mental Disorders, 3rd and 
4th text-revised edition (American Psychiatry Association) 
DSM III  
Evidence of impairment in memory (short 
and long term) 
At least one of:  
1. Impairment of abstract thinking  
2. Impaired judgment 
3. Disturbances of higher cortical 
function  
4. Personality change 
The impairments is significant to disturb 
work or normal social life 
Delirium must be excluded 
Either one of: 
1. Presence of one or more organic 
factor 
2. Disturbance cannot be explained by 
non-organic cause e.g. depression 
DSM IV-TR 
Memory impairment 
At least one of the following 
1. Aphaxia 
2. Apraxia 
3. Agnosia 
4. Disturbances in executive 
functioning 
Impairment severe to interfere with work 
and social functioning showing a decline 
from previous higher level 
The deficit does not occur in the presence 
of delirium 
The deficit may be caused by a general 
medical condition, substance abuse or 
combination of these factors 
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Table 3: Definition of dementia according to International Classification of Diseases 10th 
revision 
A Dementia is a disease of the brain, usually of chronic progressive nature, in 
which there are disturbances of multiple higher cortical functions, including 
memory, thinking, and orientation, and comprehension, calculation, learning 
capacity, language and judgment. 
B Consciousness is not clouded 
C Impairment of cognitive functions are commonly accompanied, and 
occasionally preceded, by deterioration in emotional control, social behaviour, 
or motivation 
D Dementia produces an appreciable decline in intellectual functioning, and 
usually some interference with personal activities of daily living, such as 
washing, dressing, eating, personal hygiene, excretory and toilet activities 
E The decline in functioning depends on the social and cultural setting in which 
the patient lives 
F  The symptoms must be present for at least 6 months for a confident clinical 
diagnosis 
(World Health Organization 1992) 
 
Although, this is not the case in some causes of dementia e.g. vascular dementia, where the 
cognitive decline can be rapid following a vascular insult. The other definition of dementia 
from the International Classification of Diseases 10th edition (ICD-10, WHO 1992) does not 
include a compulsory definition of the memory impairment as in the DSM definitions above, 
however ICD definition requires the presence of symptoms for at least 6 months (Table 3). 
 
2.3.1 Epidemiology of dementia 
In 2010, the World Health Organization reported a worldwide estimation of people living 
with dementia at over 35 million, with variation across regions of the world. Although the 
global prevalence is estimated at 4.7% among people aged 60 years and above, there are wide 
regional variations. In North America, prevalence is 6.9%, 6.2% in Europe, 4.0% in Asia and 
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2.6% in Africa. The present prevalence is estimated to double every 20 years, and it is 
predicted to plunge to over 65 million people by the year 2030 (Prince et al 2013). 
 
In Europe, the crude prevalence of dementia varies between 5.9% and 9.4% among people 
aged 65 and above (Berr et al. 2005), with point prevalence of 6.4% from all cause, 4.4% 
from AD, and 1.6% from vascular dementia.  Incidence increases with age and also observed 
to be higher among the elderly in Northwest Europe compared with Southern European 
countries (Lobo et al. 2000, Fratiglioni et al. 2000).  
In Finland, earlier population studies put the incidence of dementia at 256 per 100,000 
populations with female gender preponderance (Mölsa et al. 1982), increased age, and with 
more severe cases among person aged 85 and above (Sulkava et al. 1985). However, more 
recent studies among 75 years and older adults, showed the prevalence of severe dementia to 
be 22.8%; 10.6% for AD, 5.3% for vascular dementia, 5.0% for dementia with Lewy bodies 
and 1.8% of other dementing disorders (Rahkonen et al. 2003). 
 
The diagnosis of AD increases the risk of death among the elderly (Lönnroos et al. 2012). 
Comorbidities such as cardiovascular diseases, genitourinary infections, hypertension, 
hyperlipidemia, diabetes mellitus and other neurological disorders increase the rate of 
cognitive decline in dementia (Tolppanen et al. 2013). Vascular dementia remains the second 
most common form of dementia after AD (Lobo et al. 2000). It accounts for incidence rate of 
0.7 per 1000 person-years (Fratiglioni et al. 2000) and prevalence 27.6% of cases of dementia 
in Europe (Fratiglioni et al. 1999). 
 
2.3.1 Aetiology of dementia 
Dementia is a progressive irreversible syndrome with different pathological etiologies 
including AD, vascular dementia, fronto-temporal dementia, dementia with Lewy bodies, 
Huntington diseases, Pick’s diseases, Parkinson’s disease and human immune deficiency 
virus infection. It can also occur in some medical conditions such as depression, metabolic 
disorders like vitamin B12 deficiency, hypothyroidism; in which case it is a reversible 
condition. These are described in the International Classification of Diseases 10th revision 
(ICD- 10) (WHO, 1992) (Table 4).  
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2.3.1 Most common types of dementia 
 
2.3.1.1 Alzheimer's diseases  
AD is the most common form of dementia in the aging population. It is a neurodegenerative 
disease, caused by accumulation of the β-amyloid in the neuronal cell body, and tau proteins 
in the brain, which results in neurofibrillary tangles and extracellular parenchymal plaques 
(Seeley et al. 2009, Galvin 2012). It is characterized by progressive deterioration in episodic 
memory, behavior and other cognitive functions that impair the social functions and activities 
of daily living (Wegiel et al. 2003). It constitutes 61% of dementia disorders (Langa et al. 
2004), and is associated with functional disabilities that finally may necessitate 
institutionalization. 
AD occurs in two forms: the early onset that occurs before the age of 65, and the late onset 
after the age 65 years. This early onset AD occurs more rarely as it occurs in families with 
the autosomal dominant form of transmission of the mutated amyloid precursor protein 
(APP), and presenilin (PSEN1 and 2) genes.  Early onset AD may present with atypical 
clinical feature like aphasia, dysartria, myoclonus, sezuires, paraplegia and dystonia (Binetti 
et al. 2003).  Although the late onset AD does not show a mendelian form of inheritance, it is 
suggested to be highly genetic. Several studies have suggested that the apolipoprotien E4 
increases susceptibility to developing AD (Helkala et al. 1995, Kivipelto et al. 2002, Lange et 
al. 2002). 
A clinical diagnosis of a major neuro-degenerative disorder includes evidence of family 
history, decline in memory and learning with progressive decline in cognition after evidence 
of other etiologies has been ruled out. The diagnostic criteria by the National Institute Of 
Neurological Disorders and Stroke-Alzheimer's Diseases And Related Disorder (NINCDS-
ADRDA) working group are based on history, physical examinations, and further 
investigations with neuropsychological batteries, by evidence of tau proteins in the 
cerebrospinal fluid, cerebral atrophy on radiographic or magnetic images. Definite diagnosis 
can be made only with evidence of pathologic findings at postmortem (Dubois et al. 2007).  
 
Alzheimer’s disease is a condition with a spectrum of pre-symptomatic stage, mildly 
symptomatic pre-dementia and full-blown dementia. In the new guidelines for diagnosing 
AD, early stage of neuro-degeneration can be detected with the use of neuro-imaging such as 
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magnetic resonance imaging (MRI) and positron emission tomography (PET). These are able 
to detect the presence of pathologic changes before clinical expression (Torosyan and 
Silverman 2012). The MRI reveals structural changes like atrophy of the medial temporal 
lobe or the hippocampus; on PET scan evidence of amyloid deposits is seen (Dubois et al. 
2007). The histo-pathological findings of increases concentrations of β-amyloid and tau 
proteins in the cerebrospinal fluids can be used as biomarkers in predicting mild cognitive 
impairment subjects who are likely to progress to develop dementia (Dubois et al. 2010, 
Torosyan and Silverman 2012). 
 
Table 4: The classification of dementia and diagnostic codes according to International 
Classification of Diseases 10th revision (ICD-10) 
ICD-10 codes  
F 00- 00.9 Dementia in AD 
Early onset (before the age of 65) 
Late onset (after the age of 65) 
Atypical or mixed type 
Unspecified 
F01 – 01.9 Vascular dementia 
Of acute onset (develops rapidly after a stroke) 
Of multi- infarct dementia (gradual in onset following a number of minor 
ischaemic episodes in the cerebral parenchyma) 
Subcortical vascular dementia  
Mixed cortical and subcortical type 
Other type 
Unspecified 
F02 Dementia in other diseases  
 Picks disease  
Creutzfeldt-Jakob disease 
Huntington’s disease 
 Parkinson’s disease 
 HIV disease 
Other specified disease classified else where 
F03 Unspecified dementia 
World Health Organization, 1992 
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Table 5: Diagnostic criteria for Alzheimer’s diseases (National Institutes of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Dementia and Related Disorders 
Association) 
Probable Alzheimer’s diseases:  Definite Alzheimer’s diseases 
Core criteria 
Presence of an early and significant episodic 
memory impairment with: 
Gradual and progressive change in memory 
function reported by patient or relatives over 
more than 6 months. 
 
Objective evidence of significant memory 
impairment on neuropsychological test that does 
not improve with cueing or recognition. 
Episodic memory impairment can be isolated or 
in association with impairment in other cognitive 
domain 
 
AD is considered definite if the 
following are present: 
Sporadic late onset AD: Both clinical 
and histopathological evidence (brain 
biopsy or autopsy) is present 
 
Autosomal dominant AD: both the 
clinical and genetic evidence for 
autosomal inheritance (mutation on 
chromosome 1, 14 or 21) 
 
Supportive features (one or more required) 
Presence of medial temporal lobe atrophy i.e. 
Volume loss in the hippocampus, amygdala, 
entorhinal cortex on MRI) 
 
Abnormal cerebrospinal fluid biomarker such as 
the low amyloid protein, increased total tau 
concentrations, or increased phosphor-tau 
concentrations, or combination of the three. 
 
Specific pattern suggestive of Alzheimer diseases 
pathology on functional neuroimaging with PET  
Proven AD autosomal dominant mutation within 
the immediate family 
 
 
Exclusion criteria 
 
History: sudden onset of cognitive decline or 
early occurrence of gait impairment, seizures or 
behavioral changes 
 
Clinical features: focal neurological signs such as 
hemiparesis, sensory loss, visual field defects or 
extrapyramidal signs 
 
Other medical disorders severe enough to account 
for memory and related symptoms e.g. non AD 
dementia, major depression, cerebrovascular 
diseases, toxic and metabolic abnormalities 
 
Dubois et al. 2007  
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2.3.1.2 Vascular dementia 
Vascular dementia (VaD) is described as loss of cognitive functions resulting from infarction 
of the brain due to thrombosis, embolism and hemorrhage. This can also be multi infarct 
where a transient ischemic episode leads to accumulation of infarcts in the cerebral 
parenchyma; or subcortical following cerebrovascular disease (Seux 2012). Both conditions 
can also occur simultaneously in mixed vascular dementia. It is also the commonest cause of 
cognitive impairment in stroke patients, and when it occurs in the presence of AD it is termed 
mixed dementia, which comprises of 45% of cases of all dementia (Langa et al. 2004). 
 
Common risk factors include vascular risk such as hypertension, diabetes, and 
hyperlipidemia; behavioural risks such as obesity, and low physical inactivity (Levine and 
Langa 2011), or inflammatory pathology especially in younger people (Seux 2012). Aside the 
acquired pathology, genetic forms of vascular dementia occur such as the cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) 
(Chabriat et al. 2009) and sporadic amyloid angiopathy (Seux 2012). 
 
To make a diagnosis of vascular dementia, according to ICD-10, the criteria for dementia 
must be present with either of clinical evidence of focal brain damage or evidence of cerebro-
vascular accidents. Also, the criteria for case diagnosis of VaD by the National Institute of 
Neurological Disorders and Stroke with support from the Association International Workshop 
with support from the Association Internationale pour la Recherche et 1’Enseignement en 
Neurosciences (NINDS-AIREN) requires: The patient must be demented, which requires the 
presence of a decline in memory and intellectual abilities that causes impaired functioning in 
daily living; (2) There must be evidence of cerebrovascular diseases, as demonstrated by 
either history, clinical examination, or brain imaging; (3) the two disorders must be 
reasonably related (Roman et al. 1993). 
 
2.3.1.3 Fronto-temporal dementia  
Fronto-temporal dementia (FTD) refers to neurodegenerative changes in the brain, 
characterized by selective atrophy of the frontal and temporal cortex, with neuronal loss, 
gliosis and spongiosis of the superficial layers of the brain (Seeley et al. 2009). Clinical 
manifestation is characterized by progressive changes in the personality, judgment, language 
and behavior. This subtype of dementia has an early onset pattern (Neary et al. 1998). 
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Majority of the cases occur sporadically, while about 30-50% cases are familiar, with several 
autosomal dominant variants described (Seelaar et al 2011). Diagnostic criteria described in 
Table 6. 
 
Table 6: Diagnostic criteria of Fronto-temporal dementia  
Core diagnostic features  
Insidious onset and gradual progression  
Early decline in social interpersonal conduct  
Early impairment in regulation of personal conduct  
Early emotional blunting  
Early loss of insight  
Supportive diagnostic features  
A. Behavioral disorder: Decline in personal hygiene and grooming,  
Mental rigidity and inflexibility, Distractibility and impersistence, Hyperorality and dietary 
changes, Perseverative and stereotyped behavior, Utilization behavior  
 
B. Speech and language: Altered speech output, Aspontaneity and economy of speech, 
Press of speech, Stereotypy of speech, Echolalia, Perseveration, Mutism  
 
C. Physical signs: Primitive reflexes, Incontinence, Akinesia, rigidity, and tremor, Low and 
labile blood pressure  
 
D. Investigations: 
1.Neuropsychology: significant impairment on frontal lobe tests in the absence of severe 
amnesia, aphasia, or perceptuospatial disorder  
 
2. Electroencephalography: normal on conventional EEG despite clinically evident 
dementia  
3. Brain imaging (structural and/or functional): predominant frontal and/or anterior 
temporal abnormality 
Neary et al. 1998 
 
2.3.1.4 Dementia with Lewy bodies 
Dementia with Lewy bodies (DLB) is a neurodegenerative dementia characterised by 
deposition of Lewy bodies in the brain. It accounts for 15 to 20% of late onset dementias, 
making it the second most common dementing disorder among the elderly population 
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(McKeith et al. 2005). Most of the cases occur sporadically, but familial forms also exist. 
Diagnosis is often missed in clinical practice because of the close association with Parkinson 
disease. Diagnostic features are described in the Table 7. 
 
Table 7: Criteria to diagnosis of Dementia with Lewy bodies 
Central features: 
Progressive cognitive impairment which interfere with social and occupational functioning 
Prominent or persistent memory may not occur in early stage but usually present with 
progression. 
Deficit in test of attention, executive function and visuospatial ability may be prominent 
 
Core features: (two core features are sufficient for a diagnosis of probable DLB, one for 
possible DLB)  
Fluctuating cognition with pronounced variations in attention and alertness 
Recurrent visual hallucinations that are typically well formed and detailed 
Spontaneous feature of Parkinsonism 
 
Suggestive features 
REM sleep behavior disorder 
Severe neuroleptic sensitivity 
Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imaging 
Supportive features (commonly present but not diagnostic): 
Repeated falls and syncope,  
Transient, unexplained loss of consciousness,  
Severe autonomic dysfunction, e.g., orthostatic hypotension, urinary incontinence,. 
Hallucinations in other modalities, systematized delusions 
Depression 
Relative preservation of medial temporal lobe structures on CT/MRI scan 
Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity  
Abnormal (low uptake) MIBG myocardial scintigraphy 
Prominent slow wave activity on EEG with temporal lobe transient sharp wave 
Mckeith et al. 2005 
 
2.3.2 Evaluation of specific cognitive functions 
The guidelines for the diagnosis of dementia can be made using specific neuropsychological 
batteries to test for decline in each area of cognitive domain and selective anatomical 
localization (Hort et al. 2010) 
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2.3.2.1 Memory functions 
Memory, especially episodic memory, is commonly impaired in early stage of dementia, 
especially in AD. There can be disability in immediate recall and recognition, reflecting 
inability of the patient to store new information, although there is usually preservation of 
distant recent events. Similarly, semantic memory (ability to store facts and general 
knowledge) is disturbed in AD, but also in FTD and DLB, although preserved in VaD (Assal 
et al. 2003) 
The neuropsychological tools used in measuring impairment in memory include Buschke free 
and cued selective reminding test (Buschke et al. 1999, O'Connell and Tuokko 2002), or 
California verbal learning test (Lange et al. 2002); these can distinguish patients at early 
stage of Alzheimer’s dementia. In the Buschke selective reminding (BSR), participants are 
given some un-related words by a trained investigator in 20 seconds, and the participants are 
asked to name these for immediate recall. Thereafter, they are told the words missing and are 
to recall these. A sum of the total correct words is scored as short-term memory (BSRT) and 
were the words recalled more than once in succession accounting for the long-term memory 
(BSRL). The visual reproduction test (VRT) also measures memory. It includes 3 stages 
where the subjects will reproduce increasing complexity with geometric figures after 10 
seconds the figures have been shown by the examiner. Long-term memory is measured by 
reproducing the figures after 30 minutes. The accurate reproductions are scored and the 
maximum score in each subset is 21. 
 
2.3.2.2 Attention and concentration 
Attention processes are sub served by the frontal lobe, thus they are usually impaired in FTD 
and LDB dementias, but not classically in AD and VaD. Although, complex attention (e.g 
divided or selective attention) impairment may manifest in early AD, it occurs more in FTD 
and DLB (Calderon et al. 2001) 
 
2.3.2.3 Language  and Executive functions  
Verbal learning test can also be used in detecting early AD from other sub-types of dementia 
and from normal subjects without dementia, because language is intact in fronto-subcortical 
dementias. AD patients have fluent aphasia, and this may be the presenting symptom in FTD, 
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aphasia is usually absent in VaD (Grossberg and Desai 2006). Language is tested with the 
Verbal fluency test (VFT). 
Executive functions refer to ability to plan, program new information and make decisions 
based on this. Impairment occurs less in AD, especially in early stage, but occurs more in 
patients with VaD, FTD and DLB. Neuropsychological evaluation can be tested with 
Wisconsin card sorting, verbal fluency and trail making test (Nagahama et al. 2005). 
 
2.3.3 Screening test for cognitive impairment 
There are several screening tools for detecting changes in mental status. This includes but not 
limited to abbreviate mental status score (AMTS), six-item cognitive impairment test (6CIT), 
clock drawing (Sunderland et al. 1989), trail making test (Zakzanis and Mraz 2005), Mini 
Mental State Examination (MMSE) (Folstein et al. 1975). In addition, there are several 
neuropsychological test batteries used depending on region and country. Of the several tools 
used in measuring cognition, the MMSE is most commonly used.  
 
The MMSE is a global cognitive test which comprises a nine section of cognition domains: 
orientation, memory, attention, calculation, concentration, abstraction, language, writing and 
visual-spatial abilities. The language function is tested by the process of naming, repeating, 
following commands, reading and writing. Constructional abilities are assessed instructing 
the subjects to copy two intersecting pentagons (Folstein et al. 1975). The maximum score is 
30 and decline was defined as scores less than 23. The MMSE is a measure of the general 
mental state including the global cognitive function and dysfunction. It is done alongside a 
comprehensive neuropsychological evaluation, appropriate clinical assessment and the 
adequate family history. 
 
 Nowadays, only the standardized form of the MMSE is used in screening dementia, although 
with shortcoming of not been able to differentiate the different types of dementia such as the 
FTD or DLB (Hatfield et al. 2009). In addition, MMSE is a not sensitive tool in detecting 
MCI, whereas Montreal Cognitive Assessment (MoCA) 10-minute examination has been 
shown to have 100% sensitivity and 87% specificity in detecting MCI (Nasreddine et al. 
2005). 
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Also, there are more detailed neuropsychological tests batteries for screening other domains 
of cognition. Examples include AD assessment scale-cognition (ADAS-COG) (Rosen et al. 
1984), Mattis dementia rating scales (Smith et al. 1994), Cambridge mental disorders of the 
elderly examination (CAM-COG) (Roth et al. 1986), computerized Cambridge 
neuropsychological test automated battery (CANTAB), Addenbrooke’s cognitive 
examination-revised (ACE-R) (Hartfield 2009). These are mostly used in research because of 
complex administration techniques. Neuropsychological test used in diagnosing AD is 
Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Battery 
CERAD-NB). The CERAD test (Morris et al. 1989) assesses orientation, memory, verbal 
fluency, attention and constructional praxis. It is a widely used measurement, and the validity 
has been tested in several studies (Sotaniemi et al. 2012, Solomon et al. 2013).  
 
2.4 Vitamin D and cognitive functioning 
Prenatal depletion of vitamin D causes alterations in the expressions of the neurotropic factor 
resulting in learning and memory disabilities in experimental animals (Becker et al. 2005). 
Also, it has been suggested that vitamin D could reduce the accumulation of β-amyloid 
proteins by stimulating their clearance through macrophages phagocytosis (Masoumi et al. 
2009). Vitamin D mediates this effect by binding to its genomic receptor VDR where it 
mediates β-amyloid proteins phagocytosis, uptake and clearance; as well as protecting against 
neuronal apoptosis (Masoumi et al. 2009).  
 
Also, vitamin D enhances clearance of β-amyloid by promoting calcium homeostasis in the 
brain by regulating calcium channels targeted by β-amyloid peptide proteins thereby 
enhancing cerebral clearance across the blood brain barrier (Brewer et al. 2001). 
Neurodegenerative disease has been linked to neurotoxic effects of excess intracellular 
calcium resulting in neurotoxicity and neuronal cell death (Wang et al. 2001). Calcium 
deposits have been reported in areas of the brain such as in the basal ganglia, cerebral cortex 
and cerebellum, in patients with normal calcium, phosphorus but with low serum vitamin D 
(Kalueff and Tuohimaa 2007). Vitamin D modulates the reduction of calcium ion levels in 
the brain by inhibiting the expression of the L-type voltage calcium channels and by 
stimulating calcium-binding protein (i.e. parvalbumin and calbadins) (Kang and Schuman 
2000, Kalueff et al. 2004). As low serum vitamin D is common among the elderly (Virtanen 
et al. 2012), therefore, vitamin D supplementation may be important in the aging population 
to reduce intracellular cell calcium, and thus improving neuronal functions. 
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The steroid hormone vitamin D may also function in improving cognitive function through its 
activities in reversing the inflammatory changes in the nerve cells and in the hippocampus 
(Brown et al. 2003, Moore et al. 2005, Shah et al. 2012) by suppressing pro-inflammatory 
cytokines, enhancing the expression of anti-inflammatory cytokines (Annweiler et al. 2010), 
and by sensitizating macrophages (Masoumi et al. 2009). 
 
Further, vitamin D mediates detoxification effects in the brain by its up-regulation of the 
enzyme -glutamyl transpeptidase, thereby facilitating the metabolism of toxic glutathione. It 
also acts as a cellular antioxidant through it effects in reduction of oxidative stress and 
cytotoxicity from superoxide and hydrogen peroxides reactants (Ibi et al. 2001), by inhibiting 
the enzyme nitrioxide synthase (the key enzyme in the production of nitric acid), and by 
increasing the activities of choline acetytransferase in the brain (Sonnenberg et al.1986, 
Kalueff et al 2004). 
 
A positive correlation has been shown with circulating 1,25(OH)2 D3  levels and MMSE 
performance in the elderly. This further confirms that vitamin D plays a significant role in 
improving cognitive functioning in the elderly (Przybelski and Binkley 2007). In a 7 year 
prospective study, vitamin D deficiency predicted incidence of non-AD dementia (et al. 
2011), and low vitamin D concentrations have been reported in cases of untreated severe 
Alzheimer’s disease when compared with treated and non-demented controls (Shah et al. 
2012). However, the results have been inconsistent. Tables 8 and 9 shows the summary of 
previous longitudinal studies and cross sectional studies on vitamin D and cognitive 
functioning. 
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Table 8: Longitudinal studies on vitamin D and cognition 
Reference Study design Measure of vitamin D Cognition measurement Results 
Slinin, et 
al. 2010 
Both longitudinal and cross 
sectional study in male =1604 (4.6 
years) 
Serum vitamin D levels  MMSE Men with lower 25(OH)D3 levels 
seemed to have a higher odds of 
cognitive impairment:  not 
significant 
Dean et 
al. 2011 
Randomized Control Trial 
Vitamin D (one capsule 
daily, containing 5000 IU 
cholecalciferol) 
Working memory, 
response inhibition and 
cognitive flexibility. 
No association 
Annweiler 
et al. 
2012 
Randomized clinical trial, 
N=40; Women (7 years) 
Memantine + 
cholecalciferol (one 
100,000 IU drinking vial 
every 4 weeks) 
AD Assessment Scale-
cognition score 
Memantine plus vitamin D improves 
Cognition score 
Slinin, et 
al. 2012 
Both longitudinal and cross 
sectional study in women No=6257 
(4 years) 
Serumvitamin D levels MMSE Men with lower 25(OH)D3 levels 
seemed to have a higher odds of 
cognitive impairment:  not 
significant 
Breitling 
et al. 
2012 
N=1639; Mean age for women 
74.1;men 73.9, (5 years) 
Serum vitamin D levels COGTEL version A No association 
Llewelly 
2010 
N=858, mean age 65years 5.2 Serum vitamin D MMSE, TMT A and B Increases risk of decline in cognition 
with low serum vitamin D 
Motsinger 
et al.2012 
Cohort study Average Vitamin D intake 
Food frequency 
Mental health-related 
quality of life scale 
(QOL) 
<400 IU/day of vitamin D had 
significantly lower mental health-
related QOL 
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Table 9: Cross-sectional studies on vitamin D and cognition 
Reference Measure of vitamin D Cognition measurement Results 
Przybelski 
& Binkley 
2007 
Serum vitamin D MMSE 
Serum 25(OH)D concentration and MMSE showed a 
(p = 0.006) positive correlation 
Oudshoorn, 
et al. 2008 
Serum vitamin D  MMSE Serum vitamin D is associated with MMSE 
Llewellyn 
et al. 2009 
Serum vitamin D levels 
Cognitive impairment: Abbreviated 
Mental Test Score 
Low serum 25-hydroxyvitamin D is associated with 
increased odds of cognitive impairment. 
Wilkins,et 
al. 2009 
Serum vitamin D 
Measure of cognitive performance, the 
Short Blessed Test 
Vitamin D deficiency in older African Americans was 
associated with worse cognitive performance 
Buell,et al. 
2009 
Serum vitamin D levels 
Neuropsychological battery measuring 
memory, executive function, and 
attention/processing speed 
25(OH)D was positively associated with the executive 
function (β = 0.01, p < 0.01) and attention/processing 
speed factors (β = 0.01, p =.03), but not the memory 
factor (β = –0.001, p = 0.65) 
Annweiler, 
et al. 2010 
Food frequency 
questionnaire for dietary 
intake of Vitamin D 
 
 
Pfeiffer Short Portable Mental State 
Questionnaire (SPMSQ) 
Women with inadequate intakes had a lower mean 
SPMSQ score  
Llewellyn 
et al. 2011 
Serumvitamin D levels 
Measures of immediate and delayed 
verbal memory, orientation, and attention 
Vitamin D deficiency is associated with increased 
odds of cognitive impairment 
Lee et al. 
2009 
Serum vitamin D 
Rey–Osterrieth Complex Figure (ROCF) 
test, the Camden Topographical 
Recognition Memory (CTRM) test and 
the Digit Symbol Substitution Test 
(DSST) 
Lower 25(OH)D3 levels were associated with poorer 
cognitive functions 
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2.4.1 Association between vitamin D and cognitive decline 
In epidemiological studies, confounding factors have been shown to either accentuate or 
strengthen the association between an exposure and the outcome. Likewise, in various studies 
of vitamin D and cognition, there have been various confounders and effect modifies in 
vitamin D and cognition. Table 8 shows the summary of the various possible confounding 
factors and the possible effect modifiers in the association between vitamin D and cognition.  
 
Table 10 : Association between vitamin D and dementia - confounders and effect modifiers 
Variables Exposure Outcome Confounders  Effect 
modifiers 
Serum vitamin D + - - - 
Cognitive decline - + - - 
Age - + + - 
Gender - + + - 
Body mass index - + + - 
Education - + + + 
History of psychosis - + + + 
Family history of AD - + + - 
Family history of dementia - + + - 
Occupation - + + + 
Vitamin Supplement intake + + + - 
Physical activity + + + + 
Exposure =vitamin D 
Outcome= dementia or AD 
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3  OBJECTIVES OF THE STUDY 
The main objective of the study was to investigate the association between serum vitamin D3 
and cognitive impairment in Eastern Finland.  
More specifically, the objectives were 
1. To describe the cross-sectional associations of serum vitamin D3 levels and cognitive test 
performance in aging men and women in the Kuopio region in Eastern Finland 
2. To examine the association between serum vitamin D3 and later dementia and AD among 
the aging men and women in the Kuopio region in Eastern Finland 
 
The study tested the hypotheses: 
 Low levels of serum vitamin D is a risk for cognitive impairment 
 Low serum vitamin D is a risk for developing later incident dementia and AD 
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4 MATERIALS AND METHODS 
 
4.1 Study design and study population 
This study was done using the KIHD study data. KIHD is an ongoing prospective population 
based study which aimed to investigate the different risk factors for developing 
cardiovascular diseases and other chronic diseases among middle aged and aging men and 
women in Kuopio and in surrounding communities in Eastern Finland (Salonen 1988, 
Virtanen et al. 2011). The study started in1984 with the baseline sample of 3433 men aged 42 
to 60 years, who were randomly selected from the national population register in two cohorts 
(Figure 1). 
In all, 2682 men participated at the baseline examination (82.9% of those eligible). They 
were subsequently re-examined at 4 years, 11 years and 20 years. At the 11 years follow up 
examination (between the year 1998 to 2001) 920 postmenopausal women (78.4% of those 
eligible) aged 53 to 73 years were recruited and examined. 
This present study is based on the 2629 men from the initial baseline population, 506 men 
with cognition tests at 4 years, and 906 women at 11 years follow up examinations after 
excluding study participants without serum 25(OH)D3 measurements: 53 men at baseline, and 
14 women at 11 years. All participants were free from the diagnosis of dementia or 
dementing disorders at the baseline. The men were followed up after the baseline 
examinations for a mean (SD) of 20 (7.0) years while women were followed up for 12.3 (2.7) 
years. Follow-up data were available till the end of 2012 or date of death. 
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Men cohort 1 (age 
54) 
Men cohort 2 (age 
42, 48, 54, 60) 
Total 3433 
Eligible 3235 
*Participants 2682 
(82.9%) 
Participants with 
vitamin D 
measurement = 
2629 
Men (cohort 2) 
Total 1229 
Eligible 1175 
*Participants 1038 
(88.3%) 
Subjects with 
complete cognitive 
tests= 506 
Diagnosis of 
dementia and 
Alzheimer’s 
diseases from 
1. Special drug 
reimbursement 
register 
2. Hospital 
discharge 
register 
3. Cause of 
death register 
Women (post-
menopausal aged 53-
73 
Total =1351 
Eligible =1173 
*Participants=920 
(78.4%) 
Participants with 
vitamin D 
measurement = 906 
Subjects with 
complete cognitive 
test =455 
 
 
Follow-up till end 
of 2012 
Mean follow-up: 
Men= 20 ±7 years 
Women= 12.3 ±2.7 
years 
 
 
11-Year follow-up 
March 1998- February 
2001 
 
4-Year follow-up 
March 1991- 
December 1993 
Baseline  
March 1984- 
December1989 
 
 
           Figure 1: Flow chart of the study population from baseline examinations to the end of the year 2012 
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4.2 Measurements 
 
4.2.1 Data collection 
Prior to the visit to the study center, participants were mailed self-administered questionnaire. 
The participants were invited to the study center for interviews and clinical examination. 
They all underwent a health examination and an interview, which was conducted by a trained 
research nurse. Information regarding education, type of occupation, smoking status, and 
duration of regular smoking in years, alcohol consumption, and past medical condition was 
obtained using detailed questionnaires (Salonen et al. 1992) 
4.2.2 Serum vitamin D measurement 
The participants had been informed to abstain from alcohol for 3 days and from smoking 12 
hours prior to the time the blood samples were to be collected. Blood sample was collected in 
the morning between 8 am and 10 am after an overnight fast. The venous blood samples for 
25(OH)D3 analysis were taken into serum gel tubes at normal laboratory conditions, 
separated into serum after 30 minutes time for clotting, and store at -700C for 9 to 11 years 
before 25(OH)D3 concentration was analyzed (Virtanen et al. 2011).  
The serum 25(OH)D3 concentration was determined using high performance liquid 
chromatography (HPLC) (Shimadzu, Kyoto, Japan) by using diode array detector (Beckman, 
USA) as described in a report by Nurmi and collegues (Nurmi et al. 2013). Isocratic elution 
was done using 77% methanol (v/v), and chromatographic separation using discovery HS F5 
column (4x250mn; 5 µm particles, Supelco, Sigma- Aldrich, UAS) within 35 minutes of 
running time at the flow rate of 0.8 ml/min. The mobile phase was recycled within a week, at 
the rate of 2.5l for approximately 200 samples; thereby reducing the volume of solvent waste 
by 50%. Injection volume was 50 µl, and samples were stored at +40C in the auto sampler 
(Virtanen et al. 2011) 
The extraction of 25(OH)D3 was done 3 times with 3ml of hexane by shaking for 1 minute. 
The centrifuge helped to separate the samples at the various phases, while the hexane phase 
was separated into another tube. The combine extracts were evaporated under N2 and the dry 
sample was dissolved in 100 µl of 80% methanol (Nurmi et al. 2013). 
After the above method, the separation of 25(OH)D2 and 25(OH)D3 was possible, however 
the concentrations of 25(OH)D2 were mainly below the quantification limit. Therefore, only 
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the concentrations of 25(OH)D3 were reported. Vitamin D assay variation was determined by 
comparing with assay duplicates of 2 controls samples – self-made serum pool 1 and 2. Only 
the results for the 25(OH)D3 were reported, as these varies from the inter assay serum pool 1 
(53 nmol/l) by 15% and from the vitamin D control serum (Chromsystems GmbH, Germany) 
(68 nmol/l) by 16%. Variation from serum pool 2 (99 nmol/l) was 8.7% (Nurmi et al. 2013). 
4.2.3 Measurement of other risk factors 
Self-administered questionnaire was used in collecting information regarding level of 
education in years, annual income, smoking in years, history of angina pectoris, myocardial 
infarction, and other ischeamic heart diseases, previous diagnosis of hypertension, diabetes, 
current medications such as the uses of antihypertensive, anti-diabetics, anti-psychotics and 
anti-depressants, and checked by a nurse. A physician carried out re-interviews in order to 
ascertain the medical history. Dietary food intakes and nutrients were collected using a four-
day food diary, accessed from subjects during the time of bloodletting. Alcohol consumption 
in previous 12 months was assessed with quantity-frequency method using the Nordic alcohol 
consumption inventory.  
Measurement of resting systolic and diastolic blood pressure was done during each study visit 
to the center. The measurement was done between 8:00 and 10:00 am, thrice lying supine, 
twice while sitting and once standing, all with an interval of 5 minutes of rest. The mean of 
all values was used in the present analysis. Hypertension was defined as the systolic blood 
pressure of ≥140 mmHg, and or diastolic blood pressure ≥90 mmHg (Salonen et al. 1992). 
Diabetes was assessed by previous diagnosis of diabetes or fasting blood glucose levels ≥6.7 
mmol/l. The body mass index of subjects was calculated from the ratio of weight in 
kilograms and height in square meters, both measured during the study visit. The physical 
activity levels of subjects were calculated using the detailed KIHD 12-month leisure time 
physical activity questionnaire, which covers the type, duration, frequency and intensity of 
such activities (Virtanen et al. 2011) 
 
4.3 Cognitive measurement 
The MMSE is a global test for cognitive abilities measuring areas such as orientation, 
registration, attention, calculation, recall, language, and constructional ability. The maximum 
score is 30 and a score less than 27 is suggestive of mild cognitive impairment and less than 
25 was suggestive of dementia (Spering et al. 2012) 
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The Heaton visual reproduction test (VRT) produces measure of memory for non-
representative figures. Subjects are to reproduce 3 increasingly complex geometric figures 
from memory after 10 seconds from presentation time. The immediate correctly reproduce 
figures represents the short-term memory, and it is recorded as VRTI. While the long-term 
memory (VRTD), is measured by asking subjects to reproduce the figures from memory after 
30 minutes of unrelated testing. Maximum score is 21 in each test. 
The Buschke selective reminding test (BSR), the investigator reads 10 unrelated words in 20 
seconds and the subjects are asked for the immediate recall of the entire list. The process is 
repeated by instructing participants to recall the missed words, and again asked to repeat the 
entire list. The entire process is repeated 6 times.  Thereafter, the subjects are to recognize the 
learned words from a list. The total of correctly recalled words on all the trials are counted as 
the total recall (BSR). The long-term memory (BSRL) refers to words recalled more than one 
in successions. 
The trail making tests version A and version C were used. In version A, the subjects are to 
connect drawn circles numbered 1 to 25 as quickly as possible. In the original B version, the 
circles are replaced with numbers from 1 to 13, and letters from A to L. The subjects are to 
alternate between letters and alphabet. Thus, the version C was developed where letters from 
A to L are replaced with the names of months in Finnish language (this was done because, 
many persons in Kuopio area in the age group of 65 and over had not learned to produce 
letters in alphabetical order from previous experience (Koivisto 1995). The subject 
performance was judge based on the time (seconds) required to complete the tasks, and by the 
numbers of errors in numbers, letters and months. The upper time limit of 150 seconds was 
set for trail A and 300 seconds for trail C for completing the task. If a subject could not 
complete the task with in the set time limit, the uncompleted numbers, letters and months are 
counted. These test the functions of attention and ability to solve problems, i.e. executive 
functions. 
The verbal fluency test (VFT) is a measure of long-term semantic memory. Subjects are to 
generate orally as much words as possible beginning with the letters P, A, and S during a 
period of one minute, excluding proper names of persons, places and different forms of the 
same words. The scores are based on the number of correct words produced. 
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 All tests were conducted and supervised by trained personnel, and only subjects who 
completed the entire test were included in this present study. The interview and tests are 
standardized by using instruction manual for methodology of assessing and scoring the tests. 
 
4.4 Ascertainment of dementia diagnosis 
The cases of dementia or AD were detected using direct linkage to the national special 
reimbursement register, the national hospital discharge register and the national cause of 
death register.  
All antidementia drugs for treatment of AD (donepezil, rivastigmine, galantamine, and 
mamentine) are included in the national drug reimbursement system and available on 
prescription. The Social Insurance Institution of Finland (SII), maintains the drug 
reimbursement registers. To be included in the special reimbursement register, a specialist 
neurologist or geriatrician must diagnose patients with AD after a thorough history taking, 
clinical examinations including neuropsychological and laboratory tests, and brain imaging 
(Lönnroos et al. 2012). All diagnoses are made based on the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition criteria (DSM-IV) and the U.S. National Institute 
of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders 
Association (NINCDS-ADRDA) criteria for AD. This reimbursement for anti-dementia drugs 
started in February 1999. The code 307 in the reimbursement register was considered as 
indicative of AD. 
The Finnish national hospital discharge register (HILMO) includes the information of all 
public hospital admission and diagnoses based on International Classification of Diseases 
(ICD) codes. The register has been in use since 1969 (Solomon et al. 2013) with ICD-8 
codes, with ICD-9 from 1987 to 1995 and with ICD-10 from 1996 onwards.  
The Finnish national causes of death register records all the primary and contributing causes 
of death with dates using also the ICD codes. 
Linkage to the national hospital discharge register and cause of death register were done 
using the Finnish personal identification codes of patients (social security codes), these have 
been in use since 1967.  
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The diagnostic codes for screening dementia cases in the discharge and cause of death 
registers included the international ICD 8, 9 and 10 codes. The participants with dementia at 
baseline and without data on serum 25(OH)D3  were excluded.  
 
4.5 Statistical analysis 
The baseline characteristics of the participants were summarized using the mean (standard 
deviation (SD) (Table 11 and Table 12), and the tests of linear trend were performed across 
the quartiles of serum 25(OH)D3. The means were compared by using analysis of variance 
(ANOVA) for continuous variable and chi-square test for categorical variables across quartile 
of serum 25(OH)D3. One way ANOVA was used to analyze the association between quartiles 
of serum 25(OH)D3 and cognitive tests, and with post hoc test of the least significant 
difference.  
Logistic regression models were used to examine the association between quartiles of serum 
25(OH)D3 concentrations and the odds of dementia and AD for both  men and women 
participants. The highest quartile of serum 25(OH)D3 was used as the reference.  Model 1 
included adjustment for the age and date of examination. Model 2 included adjustment for 
variables that were associated with 25(OH)D3  (P value < 0.05) such as smoking, leisure time 
physical activity, and other variables that are known or suspected as confounders of 
association between serum 25(OH)D3 and dementia from the literature, such as body mass 
index, history of diabetes, diastolic blood pressure, cholesterol (HDL and LDL), previous 
myocardial infarction, use of vitamin D supplements and the season of sun exposure. 
Variables such as the total cholesterol, systolic blood pressure, hypertension and alcohol 
consumption were also tested but showed no significant change in the risk of the developing 
dementia or AD in these data.  
Tests of linear trend were conducted by assigning the median values for each category of 
exposure variable, and treating those as a single continuous variable. The statistical 
significance was set at two-sided P < 0.05.All data analysis was performed using Statistical 
Package for the Social Sciences (SPSS) version 21 for Windows.TM 
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5 ETHICAL CONSIDERATION 
The Research Ethics Committee of the University of Kuopio approved the Kuopio Ischeamic 
Heart Disease study protocol and the reference number is 143/97. All the participants gave 
informed written consent to the study. The access to the data for this study was granted on 
11th September 2013.   
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6 RESULTS 
The characteristics of study participants according to their sex-specific serum 25(OH)D3  
concentration in quartiles are shown in Table 11 and Table 12. The mean age at the 
recruitment into the study was 53 years (SD 5.1, range: 42.0 - 61.3 years) for men and 63.2 
years (SD 6.5, range: 53.5 - 72.7 years) for women. The mean serum 25(OH)D3 
concentration was 43.4 nmol/l (SD 18.9, range: 7.8 - 136.1 nmol/l) for men, and 44.8 nmol/l 
(SD 17.6, range: 8.5 - 112.8 nmol/l) for women. 
An overview of the participants’ characteristics showed that subjects in the highest serum 
25(OH)D3 concentration quartile smoked less cigarettes, expended more energy during 
leisure time physical actives and had their blood samples for vitamin D analysis drawn during 
the summer months. While, subjects in the lowest serum 25(OH)D3 concentration quartile 
had less education, higher body mass index, and higher daily energy intake. The was 
statistical significant difference between men who smoked less (P = 0.001), expended more 
energy during their leisure (P = <0.001) and those who had less energy intake (P = 0.01) 
across quartiles of serum 25(OH)D3.  Similarly, statistical significant difference occur among 
women expended more energy during their leisure (P = 0.03) and those with less body mass 
index (<0.001) across quartiles of serum 25(OH)D3 . 
Table 13 and 14 shows a cross sectional analysis of cognitive test performance for men at 4-
year follow-up examination and for women who were recruited to the study at 11 years 
follow-up examination respectively, across concentration of serum 25(OH)D3. Among the 
511 men examined, no statistically significant was observed across quartiles of 25(OH)D3  on 
scores of cognitive performance (Table 13), while among the 455 women tested, the verbal 
fluency test (VFT) showed a statistically significantly difference across quartiles of serum 
25(OH)D3 (P trend = 0.02). The difference occurs in the mean (SD) score among the subjects 
in the highest 25(OH)D3  quartile 41.7 (14.5) and the lowest category 36.6 (11.7) with least 
significant difference (LSD) post hoc test P = 0.004 (Table 14). 
After the mean follow-up periods of 20 years (SD 7.0) for men and 12.3 years (SD 2.7) for 
women, the incidence of dementia and AD were 267 (10.2%) and 181(6.9%) for men, and   
73(8.1%) and 69(7.6%) for women (Table 15 and 16). AD constitute the highest occurring 
cause of dementia among the participants accounting for 67.8% and 94.5% of all cases of 
dementia among men and women respectively. More cases of dementia and AD occurred 
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among subjects in the lower serum 25(OH)D3 quartile than among those in the higher quartile 
of serum 25(OH)D3 concentration.  
 
Table 11: The baseline characteristics of men (n=2629) across quartiles of serum 25(OH)D3  
concentrations 
 Serum 25(OH)D3  concentrations in quartiles (nmol/l)  
Characteristics1 
1 (7.8-28.89) 
(n=657) 
2 (28.9-40.12) 
(n=657) 
3 (40.14-54.94) 
(n=658) 
4 (54.95–136.08) 
(n=657) 
P-trend2 
Age (years) 52.8 (5.0) 52.9 (5.2) 53.1 (5.3) 53.5 (5.0) 0.01 
Season for 
vitamin D*, n 
(%) 
27 (4.1) 86 (13.1) 169 (25.7) 348 (53.0) <0.001 
Smoking (pack 
years) 
10.3 (17.5) 8.9 (16.9) 7.5 (16.5) 7.2 (15.5) 0.001 
Leisure time 
physical activity 
(kcal/day) 
115.2 (156.6) 128.9 (155.9) 153.6 (197.1) 165.5 (180.1) <0.001 
Body mass index 
(kg/m2) 
26.8 (3.7) 23.9 (3.5) 27.0 (4.0) 26.8 (3.4) 0.74 
Alcohol (g/week) 74.2 (132.3) 76.4 (117.9) 77.1 (153.9) 74.9 (140.8) 0.91 
Education (years) 8.4 (3.3) 8.8 (3.5) 8.6 (3.4) 8.7 (3.5) 0.39 
Hypertensive, n 
(%) 
404 (15) 393 (15) 395 (15) 397 (15) 0.93 
Diabetics, n (%) 46 (1.7) 36 (1.4) 44 (1.7) 29 (1.1) 0.17 
Myocardia 
infarction, n (%) 
163 (6.2) 151 (5.7) 184 (7.0) 160 (6.1) 0.20 
Energy intake 
(Mkcal/d) 
2.4 (0.7) 2.4 (0.7) 2.3 (0.6) 2.3 (0.6) 0.01 
Total serum 
cholesterol 
(mmol/l) 
5.9 (1.1) 5.9 (1.1) 5.9 (1.1) 6.0 (1.1) 0.23 
*Season for vitamin D = % of those who had their sample taken during the summer months 
June to September. 1All values are in mean (SD), and frequency (%), 2ANOVA 
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Table 12: The baseline characteristics of women (n=920) across quartiles of serum 25(OH)D3  
concentrations 
 Serum 25(OH)D3  concentrations in quartiles (nmol/l)  
Characteristics1 
1 (8.54-29.96) 
(n=204) 
2 (30.05-42.11) 
(n=224) 
3 (40.15-54.38) 
(n=229) 
4 (54.40-112.77) 
(n=249) 
P- trend2 
Age (years) 63.1 (6.6) 63.4 (6.7) 63.3 (6.3) 63.0 (6.5) 0.69 
Season for 
vitamin D*, n 
(%),  
28 (13.7) 58 (25.9) 72 (31.4) 111 (44.6) <0.001 
Smoking (pack 
years), 
2.7 (8.7) 0.7 (4.4) 1.3 (6.1) 1.5 (6.3) 0.07 
Leisure time 
physical activity 
(kcal/day) 
161.8 (186.4) 178.8 (204.1) 183.1 (148.8) 205.1 (263.5) 0.03 
Body mass index 
(kg/m2) 
29.2 (5.7) 28.6 (5.0) 28.2 (5.0) 27.4 (4.8) <0.001 
Alcohol 
(g/week) 
19.7 (47.2) 18.9 (38.3) 16.7 (28.6) 20.3 (35.5) 0.98 
Education 
(years) 
9.3(3.3) 9.5 (3.3) 9.7 (3.3) 10.1 (3.4) 0.01 
Hypertensive, n 
(%) 
136 (66.7) 157 (70.1) 153 (66.8) 150 (25) 0.14 
Diabetics, n (%) 24 (11.8) 20 (8.9) 26 (11.4) 22 (8.8) 0.62 
Myocardia 
infarction, n (%) 
62 (30.4) 55 (24.6) 61 (26.6) 74 (29.7) 0.48 
Energy intake 
(Mkcal/d) 
1.56 (0.45) 1.54 (0.41) 1.55 (0.45) 1.57 (0.39) 0.75 
Total serum 
cholesterol 
(mmol/l) 
5.7 (0.9) 5.7 (0.9) 5.6 (1.0) 5.7 (0.9) 0.26 
*Season for vitamin D = % of those who had their sample taken during the summer months 
June to September 1All values are in mean (SD), and frequency (%), 2ANOVA 
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Table 13: Cognition performance among men (N = 511) across quartiles of serum 25(OH)D3  
concentrations at 4 years follow up 
Values expressed as mean (SD), MMSE: mini mental state examinations; TMTA trail making 
test version A, time in seconds, TMTC trail making test version C, time in seconds; VRTI 
visual reproduction test immediate recalled words, VRTD visual reproduction test delayed 
recalled words; BSRR, Buschke selective reminding test-total recall, BSRL Buschke 
selective reminding long term recall; VFT: verbal fluency test- right words. 1P- trend is 
ANOVA 2 P- trend is least significant difference post hoc test 
 
 
 
 
 Serum 25(OH)D3  concentrations in quartiles (nmol/l)   
Cognition test 
 1(7.8–28.89) 
n=96 
2 (28.9–40.12) 
n=122 
3 (40.14–54.94) 
n=144 
4 (54.95–136.08) 
n=149 
P- trend1 P- trend2 
MMSE 26.9 (2.4) 27.2 (1.9) 27.1 (2.1) 27.1 (2.0) 0.14 0.10 
BSR 34.6(8.5) 35.2 (8.5) 34.5 (8.6) 33.7 (8.5) 0.38 0.83 
BSRL 26.3(18.4) 27.8 (11.3) 27.1 (11.3) 26.5 (10.7) 0.73 0.90 
TMT A 54.3(18.4) 50.6 (19.2) 52.7 (19.6) 52.4 (18.4) 0.31 0.15 
TMT C 127 (70) 119 (63) 128 (66) 127 (64) 0.63 0.63 
VRTI 11.4 (4.1) 11.1 (3.7) 11.8 (3.6) 10.9 (3.4) 0.18 0.55 
VRTD 8.6 (4.7) 8.4 (4.1) 9.2 (4.4) 8.4 (4.0) 0.38 0.87 
VFT 31.6 (12.7) 33.2 (13.7) 32.0 (11.5) 33.1 (13.1) 0.42 0.16 
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Table 14: Cognition performance among women (N = 455) across quartiles of serum 
25(OH)D3  concentrations at 11 years examinations 
 
Serum 25(OH)D3  quartiles (nmol/l) 
  
Cognition 
test 
 
1 (8.54-29.96) 
(n=97) 
2(30.05–42.11) 
(n=117) 
3(42.15–54.38) 
(n=119) 
4(54.40–112.77) 
(n=122) 
P- trend1 P- trend2 
MMSE 26.3(2.3) 26.3(2.1) 26.0(2.3) 26.7(2.2) 0.16 0.29 
BSR 38.7(9.1) 43.5(39.4) 41.8(28.6) 39.7(8.1) 0.51 0.79 
BSRL 28.4(14.9) 34.1(43.0) 32.9(33.4) 30.1(13.3) 0.47 0.68 
TMT A 59.9(22.9) 55.7(21.8) 57.7(21.3) 58.9(23.9) 0.54 0.18 
TMT C 149(76) 138(66) 144(70) 138(71) 0.58 0.25 
VRTI 10.2(3.4) 10.7(3.4) 10.4(3.5) 11.3(3.5) 0.10 0.03 
VRTD 7.7(4.0) 8.0(3.6) 7.5(4.3) 8.6(3.8) 0.14 0.10 
VFT 36.6(11.7) 37.3(12.0) 38.8(12.7) 41.7(14.5) 0.02 0.004 
Values expressed as mean (SD), MMSE: mini mental state examinations; TMTA trail making 
test version A, time in seconds, TMTC trail making test version C, time in seconds; VRTI 
visual reproduction test immediate recalled words, VRTD visual reproduction test delayed 
recalled words; BSRR, Buschke selective reminding test-total recall, BSRL Buschke 
selective reminding long term recall; VFT: verbal fluency test- right words. 1P- trend is 
ANOVA 2 P- trend is least significant difference post hoc test 
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Table 15: Distribution of dementia and Alzheimer’s diseases among men across quartiles of 
serum 25(OH)D3  concentrations 
 
Serum 25(OH)D3  quartiles (nmol/l) 
 
 
1 (7.8–28.89) 
(n=657) 
2 (28.9–40.12) 
(n=657) 
3 (40.14–54.94) 
(n=658) 
4 (54.95–136.08) 
(n=657) 
Total n (%) 
(n = 2629) 
Dementia,n(%) 69 (10.5) 70 (10.7) 57 (8.7) 71 (10.8) 267 (10.2) 
AD,n (%) 48 (7.3) 49 (7.5) 40 (6.1) 44 (6.7) 181 (6.9) 
 
 
Table 16: Distribution of dementia and Alzheimer’s diseases among women across quartiles 
serum 25(OH)D3  concentrations 
 Serum 25(OH)D3  quartiles (nmol/l)  
 
1 (8.54–29.96) 
(n=204) 
2 (30.05–42.11) 
(n=224) 
3 (40.15–54.38) 
(n=229) 
4 (54.40–112.77) 
(n=249) 
Total n (%) 
(n = 906) 
Dementia,n(%) 26 (12.7) 16 (7.1) 12 (5.2) 19 (7.6) 73 (8.1) 
AD n, (%) 24 (11.8) 16 (7.1) 12 (5.2) 17 (6.8) 69 (7.6) 
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Table 17: Risk of dementia and Alzheimer’s diseases across quartiles of serum 25(OH)D3  
concentrations among men 
 Serum 25(OH)D3  quartiles (nmol/l)  
 1 (7.8–28.89) 2 (28.9–40.12) 3 (42.15–54.38) 4 (54.40–112.77) P trend 
Model 1 
Dementia 
1.07 (0.75–1.53) 1.05 (0.74–1.51) 0.81 (0.56–1.18) 1 (Ref) 0.43 
Model 2 
Dementia 
1.24 (0.83–1.86) 1.15 (0.78–1.69) 0.87 (0.59–1.29) 1 (Ref) 0.14 
Model 1 
AD 
1.22 (0.79–1.87) 1.21 (0.79–1.86) 0.94 (0.60–1.47) 1 (Ref) 0.22 
Model 2 
AD 
1.38 (0.85–2.24) 1.28 (0.81–2.04) 1.01 (0.63–1.60) 1 (Ref) 0.12 
All values are hazard ratios (95% confidence interval). Model 1 is adjusted for age, and date 
of examination. Model 2 is adjusted for age, date of examination, smoking, body mass index, 
leisure time physical activity, mean diastolic blood pressure, high-density lipoprotein, low-
density lipoprotein, diabetes, myocardial infarction, vitamin D supplement intake and season 
for vitamin D 
 
 
The subjects in the highest serum 25(OH)D3 were used as reference in the logistic regression 
models (Table 17 and 18). Among the men there was no statistical significant differences in 
the risk of dementia or AD by vitamin D concentrations. In the fully adjusted model, men in 
the lowest quartile of serum 25(OH)D3 concentration had non-significant 1.24 fold (95% CI 
0.83-1.86,  P = 0.3) risk of developing dementia, 1.15 fold  (95% CI 0.78-1.69,  P = 0.48) 
risk in the second quartile, and 19% protection (95% CI 0.59-1.29, P = 0.49) in the third 
quartile, P-trend = 0.14; while for AD the risk was 1.38 fold (95% CI 0.83-2.10, P = 0.20), 
1.28 (95% CI 0.82-2.12, P = 0.29) and 1.01 (95% CI 0.63-1.60, P =0.98) P-trend = 0.12 in 
the first, second and third quartiles of vitamin D respectively, when compared to the subjects 
in the fourth vitamin D quartiles (Table 17). 
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Table 18: Risk of dementia and Alzheimer’s diseases across quartiles of serum 25(OH)D3  
concentrations for women 
 Serum 25(OH)D3  quartiles (nmol/l)  
 1 (7.8–28.89) 2 (28.9–40.12) 3 (42.15–54.38) 4 (54.40-112.77) P trend 
Model 1 
Dementia 
1.80 (0.94–3.46) 0.85 (0.42–1.73) 0.64 (0.30–1.39) 1 (Ref) 0.06 
Model 2 
Dementia 
2.74 (1.31–5.72) 1.12 (0.53–2.26) 0.81 (0.36–1.79) 1 (Ref) 0.01 
Model 1 
AD 
1.85 (0.83.3.64) 0.97 (0.47–2.00) 0.73 (0.34–1.60) 1 (Ref) 0.06 
Model 2 
AD 
2.76 (1.28–5.91) 1.26 (0.58–2.71) 0.91 (0.40–2.05) 1 (Ref) 0.01 
All values are hazard ratios (95% confidence interval). Model 1 is adjusted for age, and date 
of examination. Model 2 is adjusted for age, date of examination, smoking, body mass index, 
leisure time physical activity, mean diastolic blood pressure, high-density lipoprotein, low-
density lipoprotein, diabetes, myocardial infarction, vitamin D supplement intake and season 
for vitamin D 
 
 
However, in the women cohort, there was statistically significant increase in the risk of 
developing dementia after full adjustment for potential confounding: 2.74 fold (95% CI 1.31-
5.72, P = 0.01), 1.12 (95% CI 0.53-2.26, P = 0.78) and 0.81 (95% CI 0.36-1.79, P = 0.60) P-
trend = 0.01; for AD was 2.76 (95% CI 1.28-5.91, P = 0.01), 1.26 (95% CI 0.58-2.71, P = 
0.56), 0.91 (95% CI 0.40-2.05, P = 0.81) P-trend = 0.01 in the first, second and third 
quartiles of serum vitamin D concentrations when compared to the highest quartile of serum 
25(OH)D3 (Table 18). 
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7 DISCUSSION 
In this population based prospective and cross sectional analyses, we investigated the risk of 
low circulating serum vitamin D status on incident dementia and AD, and the association of 
serum vitamin D on cognitive test performance. A statistically significant difference was 
observed among women in verbal fluency test (VFT) performance and an increase in the risk 
of dementia and AD in subjects in the lowest serum vitamin D quartiles (<30 nmol/l) when 
compared with the highest vitamin D quartiles (>54 nmol/l), whereas there was no statistical 
significance observed among the men cohort. 
 
7.1 Vitamin D and cognitive function 
Reports from previous studies on the association between serum vitamin D and cognitive 
performance have been inconsistent. While some studies had reported no association between 
low levels of serum vitamin D concentration and cognition (McGrant et al. 2007), some had 
reported low vitamin D to be associated with poor cognitive function (Buell et al. 2009, 
Seamans et al. 2010, Slinin et al. 2010, Breitling et al. 2012, Annweiler et al. 2012), and 
cognitive decline or impairment (Llewenly et al. 2009, 2011, Slinin et al. 2012, Annweiler et 
al. 2010). This inconsistency may be partly due to different assessment tools used in 
determining cognitive performance in these studies. 
 
Studies defining cognitive impairment as poor performance on the general cognitive 
functioning test such as MMSE (Przybelski and Binkeley 2007, Slinin et al. 2012), modified 
MMSE (Slinin et al. 2010) or the abbreviated mental test (AMT) (Llewellyn et al. 2009) have 
found an association between low level of serum concentrations of vitamin D and cognitive 
impairment. In the present study, there is significant association on verbal fluency (VFT) 
among women with high serum vitamin D compared with those with very low concentrations 
(P = 0.02), but no statistically significant findings in men.  
 
The differences observed in this study supports the findings of Seamans and colleagues, who 
reported significant differences in cognitive performances between the highest and lowest 
tertiles of serum vitamin D in women, but no difference in men (Seamans et al. 2010). 
Further, we found no significant association with test of executive functioning (TMT A and 
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C) either in women or in men. This finding is similar to that reported by Annweiler and 
colleagues in 2010 and Slinin and colleagues in 2012 where vitamin D status was not 
significantly associated with TMT B test performance either in men or women (Annweiler et 
al. 2010, Slinin et al. 2010, 2012). This is in contrast to the report of Buell and colleagues in 
2009, who found an association with test of executive functioning (TMT A and B) and 
vitamin D status, and Llewelly and collegues who observed significant difference in TMT B 
but not in TMT A test performance among free living elderly persons (Buell et al. in 2010, 
Llewelly et al. 2009). 
 
7.2 Vitamin D and dementia  
Also, our findings on the increase in risk of developing later dementia and AD among 
subjects with very low serum vitamin D concentrations are in line with previously reported 
prospective epidemiological studies (Buell et al. 2010 Afzal et al. 2013). In a recent report 
among Danish population, subjects with serum vitamin D concentration less than 25 nmol/l 
had 25% increase risk in developing AD compared to subjects with concentrations >50 
nmol/l (Afzal et al. 2013). 
Vitamin D insufficiency has been described to be associated with impairments in 
physiological and neuropsychological functions (Menant et al. 2011). Epidemiological 
studies had revealed association between low circulating serum vitamin D and pathologies 
typically found in AD patients.  A study had reported a positive correlation between serum 
concentration of vitamin D and regional cerebral blood flow in the left precuneus cortex 
among AD patients suggesting a potential neuroprotective effect of vitamin D against 
neurodegeneration (Farid et al 2012). Similarly, some studies had reported increases in the 
incidence of stroke, white mater hyper intensities and multiple large vessel infarcts in 
dementia subjects with low serum vitamin D (Vermeer et al. 2003, Buell et al. 2010). 
 
7.3 The mechanism of vitamin D in preventing dementia 
The mechanisms of vitamin D in the prevention of dementia and cognitive decline are 
plausible especially in dementia of AD type. Circulating serum vitamin D has been 
implicated in the increased activities of the choline acetytransferase enzyme (Sonnenberg et 
al 1986). Also it has been observed to increase clearance of β-amyloid protein by 
54 
 
macrophages in patients with AD (Masoumi et al. 2009, Mizwicki et al. 2012). Similarly, it 
protects neuronal cells from apoptosis (Wang et al. 2001) and reduces neurotoxicity from 
excess intracellular calcium by down-regulating voltage sensitive L-type calcium channels 
(Brewer et al. 2001); and up regulation of the nerve growth factors, these functions are lost in 
the neurodegenerative process in AD (Gezen-Ak et al. 2011). A previous longitudinal study 
had found improvement in cognitive performance among elderly women with high weekly 
vitamin D supplements intake (Annweiller et al 2010). There is clearly a need for larger 
randomized controlled trials to show the causal association of vitamin D in cognition. 
 
7.4 Strength of this study 
The strength of this study includes the relatively large population and randomly selected 
sample of aging men and women, with a long mean follow-up of 20 (7.0) years for men and 
12.3 (2.7) years for women. The prospective design allows for some causal interpretation.  
There was no loss to follow up as all subjects have individual personal identification code 
and are traceable in the national registers. 
In addition, the diagnoses of dementia and AD from the three Finnish clinical register system 
since 1972 have been shown to be sensitive and with strong positive predictive values. Thus, 
the diagnoses are valid for use in population-based studies (Solomon et al. 2013) 
Also, we were able to adjust for many of the possible confounders for dementia and AD such 
as vascular risk factors like smoking, body mass index, physical activity and serum 
cholesterol; and medical conditions such as hypertension diabetes and myocardial infarction. 
 
7.5 Limitation of this study 
A major limitation of this study is the one time measurement of vitamin D at the baseline, 
which may not be a total indicator of the later serum concentrations during the follow-up 
periods, however, studies have shown that single measurement of 25(OH)D3  is a reasonable 
predictor of long term exposure to plasma 25(OH)D3 (Jorde et al. 2010).  
The mean serum 25(OH)D3 concentration in our cohort is low compared to other cohorts in 
other studies (Llewellyn et al. 2009, Seamans et al. 2010, Afzal et al. 2013), thus this limited 
the broader range of values of 25(OH)D3  to be analyzed. 
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In this study, limited numbers of the dementia subtypes could be identified among the 
subjects; therefore our data reflects subjects that are diagnosed with any type of dementia or 
AD. Also, diagnostic activity may have been low before the symptomatic treatment for AD 
was available and reimbursed by the SII i.e. before 1999. 
The cross-sectional design for testing cognitive performance across concentration of 
25(OH)D3 cannot be used to make a causal inferences. Also, multiple cognitive testing 
methods performed may have contributed to some false positive findings. In the men cohort, 
baseline serum 25(OH)D3 was used to assess the cognitive performance at 4-year follow-up 
examinations as against women cohort in which serum 25(OH)D3 measurement at 11-year 
examination was used to assess cognitive performance in the same years.  
 
8 CONCLUSION 
In summary, we observed in these prospective and cross-sectional analyses there exist an 
association between low levels of circulating serum vitamin D concentrations and cognitive 
impairment in the verbal fluency among women. However, the association is non-linear. We 
also observed that there exists an increase risk among aging individuals with very low serum 
vitamin D in developing later dementia or AD, and this risk increases when adjusted for 
effects of potential confounding factors. However, confirmation of causality is needed in a 
larger cohort studies and randomized controlled trials. 
 
9 RECOMMENDATIONS 
More future vitamin D trials may be required to establish the causal role of vitamin in 
dementia. There may be need also to increase vitamin D serum levels in the public especially 
among the aging populations. This can be achieved by public education on the intake of 
vitamin D fortified food and supplements intake to reduce the risk of later dementia or AD. 
Also, there should be an increase in awareness on the need to reduce other risk such as 
smoking, low physical activity and body mass index, in order to reduce the risk of developing 
dementia later in life.  
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